BioCardia, Inc. — Form 8-K
Filed September 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
BioCardia announced CEO Peter Altman will present at H.C. Wainwright conference (September 14-16, 2026) on CardiAMP cell therapy progress. The company is preparing a Shonin pre-market submission to Japan's PMDA in Q4 2026 and the FDA confirmed in June that the CardiAMP HF II pivotal trial may support U.S. Premarket Approval. No new financial figures, partnerships, or material transactions are disclosed; this is a conference presentation announcement.
Why this rating
Routine investor conference disclosure with no new material contracts, funding, or trial data. Regulatory timelines reiterate prior guidance; announcement is primarily procedural.
See more from September 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.